false
0001043961
0001043961
2024-01-01
2024-01-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of report (Date of earliest event reported):
January 1, 2024
PRECIPIO,
INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36439 |
|
91-1789357 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
4 Science Park, New Haven,
CT 06511
(Address of principal executive
offices) (Zip Code)
(203) 787-7888
(Registrant's telephone
number, including area code)
Not
Applicable
(Former name, former address and former fiscal year, if changed since last report date)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Securities registered pursuant to Section 12(b) of the Act: |
Title of each class |
Ticker symbol(s) |
Name of each exchange on which
registered |
Common Stock, $0.01 par value per share |
PRPO |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
Act of 1934.
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Director
On January 1, 2024, the board
of directors (the “Board”) of Precipio, Inc. (the “Company”) accepted the resignation of Douglas Fisher as a member
of the Board, Audit Committee and Compensation Committee, and any other committee thereof, effective January 1, 2024. Effective January
1, 2024, Dr. Fisher became an observer of the Board, and in such capacity, Dr. Fisher will attend, in a non-voting observer capacity,
meetings of the Board. Dr. Fisher did not resign due to any disagreement with the Company on any matter relating to its operations, policies
or practices.
Appointment of Director
On January 1, 2024, upon the
recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Christina Valauri to fill the
vacancy left by Mr. Fisher’s resignation and to serve as a class II director of the Company, effective January 1, 2024, and until
her term expires at the 2026 annual meeting of stockholders, at which time she will stand for election by the Company’s stockholders
or her earlier resignation, retirement or removal. In connection with her appointment to the Board, Ms. Valauri was appointed as a member
of the Nominating and Corporate Governance Committee. [The Board determined Ms. Valauri is independent under the listing standards of
Nasdaq.]
As a non-employee director,
Ms. Valauri will be compensated for service under the Company’s policy for non-employee director compensation. In connection with
her election and pursuant to the Company’s 2017 Stock Option and Incentive Plan, as amended, (the “Plan”), the Company
granted Ms. Valauri stock options (each an “Option” and together, the “Options”) to purchase an aggregate of 103
and 259 shares, respectively, of the Company’s common stock (“Common Stock”), par value $0.01 per share, each at an
exercise price per share equal to the closing price of the Company’s Common Stock on January 2, 2024 (the “Grant Date”).
The Option to purchase 103 shares shall vest equally on a monthly basis over a twelve-month period commencing on the Grant Date, and the
Option to purchase 259 shares shall vest equally on a monthly basis over a thirty-six-month period commencing on the Grant Date.
Ms. Valarui does not
have a family relationship with any of the executive officers or directors of the Company. Ms. Valarui is not a party to any
transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or
understandings between s. Valarui and any other persons pursuant to which Ms. Valarui was selected as a director of the Company. Ms.
Valarui will enter into an indemnification agreement with the Company consistent with the form of indemnification agreement
entered into between the Company and its existing non-employee directors.
The Company’s Audit
Committee now consists of David S. Cohen, Richard Sandberg and Kathleen D. LaPorte, with Ms. LaPorte serving as the Chair of the Audit
Committee. The Compensation Committee now consists of David S. Cohen and Ron A. Andrews, with Mr. Cohen serving as Chair of the Compensation
Committee. The Nominating and Corporate Governance Committee now consists of Jeffrey Cossman and Christina Valauri, with Dr. Cossman serving
as the Chair of the Nominating and Corporate Governance Committee.
Item 7.01 Regulation FD Disclosure.
On January 2, 2024, the Company issued a press
release announcing the resignation of Dr. Fisher and the appointment of Ms. Valauri. A Copy of the Press Release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PRECIPIO, INC. |
|
|
|
By: |
/s/ Ilan Danieli |
|
Name: |
Ilan Danieli |
|
Title: |
Chief Executive Officer |
Date: January 2, 2024
Exhibit 99.1
Precipio Announces
Christina Valauri joins the Board of Directors
Douglas
Fisher, MD will step down as Director, and remain as a board observer
NEW HAVEN, CT, Globenewswire
– (January 2, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is
pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024. Ms. Valauri is joining Precipio’s board
to support management’s understanding of and interaction with the capital markets, as we look towards 2024 to be an important period
for our company from both a business growth, and financial perspective.
Ms.
Valauri brings a 30-year proven track record as a senior healthcare analyst and has held leadership roles that include US and Global
Head of Equity Research and Managing Director at Cantor Fitzgerald, and senior equity research management roles at firms including ING,
Credit Lyonnais (acquired by Credit Agricole), and Natixis.
She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received
the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges. .
Ms. Valauri is the founding
partner and CEO of Sagestone Advisory, LLC. Her background in equity securities research has provided a deep base of experience in pharmaceutical,
biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations,
as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory,
go-to-market strategies, potential mergers and acquisitions, and IPOs.
Ms. Valauri currently
serves as an Entrepreneur In Residence at Weill Cornell Medicine BioVenture eLab where she applies her skills and experience in life
sciences and business to support the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of
researchers, and clinicians. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University.
“As we continue
to execute on our goals, and increase our interaction with the public markets, it's incredibly helpful to have someone like Christina
who knows what the investor audiences are looking to see in an early stage growth company,” said Ilan Danieli, Precipio’s
CEO, “In the few months that I have had the pleasure of getting to know Christina, she has already dramatically contributed to
our knowledge and understanding of what drives the conversion of a company’s business success to an increase in shareholder value.
We are fortunate to have her join our board.”
After serving on Precipio’s
board of directors for 6 years, Douglas Fisher M.D. is stepping off the board to maintain a board of 7 directors and will remain as an
observer moving forward.
“Although Doug
is formally stepping down as a director, I am delighted that our relationship with him is not ending,” said Ilan Danieli, CEO.
“Doug has played an integral role in the company’s leadership; his combination of medicine and business education, and his
experience in early stage and public companies has and will continue to be invaluable to the company.”
“I’m excited
about Precipio’s prospects moving forward, and Ms. Valauri brings excellent experience to help accelerate our interactions with
public market investors. I’m looking forward to continuing to support the company moving forward”, said Doug Fisher, MD.
About Precipio
Precipio
is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses
by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved
laboratory workflow, and ultimately deliver better patient outcomes which reduce healthcare expenses. Precipio develops innovative technologies
in our clinical laboratory where we design, test, validate, and run these products intended to improve diagnostic outcomes. Precipio
then commercializes its technologies as proprietary products that serve the global laboratory community and further scales Precipio’s
reach to eradicate misdiagnosis.For more information, please visit www.precipiodx.com.
Please follow us on LinkedIn, X@PrecipioDx
and on Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements
about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows,
plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs,
assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,”
“will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect
our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking
statements. These forward-looking statements are only predictions based on management’s current expectations. These statements
are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed
or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk
Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and our other reports filed with the U.S.
Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this
press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law,
we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
Ext. 523
v3.23.4
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Precipio (NASDAQ:PRPO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Precipio (NASDAQ:PRPO)
Storico
Da Mag 2023 a Mag 2024